Yüklüyor......
Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single‐Dose and Multiple‐Ascending‐Dose Phase 1 Studies in Healthy Adults
Lemborexant, a dual orexin receptor antagonist, is approved for the treatment of insomnia and is under investigation for treating other sleep disorders. Here we summarize pharmacokinetic, pharmacodynamic, and safety data from 3 randomized, double‐blind, placebo‐controlled phase 1 studies: single asc...
Kaydedildi:
| Yayımlandı: | Clin Pharmacol Drug Dev |
|---|---|
| Asıl Yazarlar: | , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley and Sons Inc.
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7891412/ https://ncbi.nlm.nih.gov/pubmed/32468649 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.817 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|